Abstract:Background: Sulbactam dosing for Acinetobacter baumannii infections has not been standardized due to limited available pharmacokinetics/pharmacodynamics (PK/PD) data. Herein, we report a comprehensive PK/PD analysis of ampicillin-sulbactam against A. baumannii pneumonia. Methods: Twenty-one A. baumannii clinical isolates were tested in the neutropenic murine pneumonia model. For dose-ranging studies, groups of mice were administered escalating doses of ampicillin-sulbactam. Changes in log10cfu/lungs relative to 0 h were assessed. Dose-fractionation studies were performed. Estimates of the percentage of of time during which the unbound plasma sulbactam concentrations exceeded the MIC (%fT > MIC) required for different efficacy endpoints were calculated. The probabilities of target attainment (PTA) for the 1-log kill plasma targets were estimated following clinically utilized sulbactam regimens. Results: Dose-fractionation studies demonstrated time-dependent kill. Isolates resistant to both sulbactam and meropenem required three times the exposures to achieve 1-log kill; median [IQR] %fT > MIC of 60.37% [51.6-66.8] compared with other phenotypes (21.17 [16.0-32.9] %fT > MIC). Sulbactam standard dose (1 g q6h, 0.5 h infusion) provided >90% PTA up to MIC of 4 mg/L. Sulbactam 3 g q8h, 4 h inf provided greater PTA for isolates with sulbactam-intermediate susceptibility (8 mg/L, 100% versus 86% following the standard dose). Despite the higher exposure following 3 g q8h, 4 h inf, PTA was ≤57% among sulbactam-resistant/meropenem-resistant isolates. Conclusion: Sulbactam standard dose is a valuable regimen across sulbactam-susceptible isolates while the high-dose extended-infusion provides additional benefit against sulbactam-intermediate isolates. Given that most of the sulbactam-resistant A. baumannii isolates are meropenem-resistant, high-dose prolonged-infusion regimens are not expected to be effective as monotherapy against infections due to these isolates.

Clinical evaluation of sulbactam/ampicillin

A randomized controlled open study of ampicillin/sulbactum in the treatment of 172 cases with bacterial infections

Bacteriological Efficacy of Amoxicillin/sulbactam on Acute Bacterial Infections

Clinical Randomized Controlled Trial of Amoxycillin-sulbactam Injection in the Treatment of Bacterial Infection

Multicenter Clinical Study on Piperacillin/Sulbactam for Treatment of Respiratory and Urinary Tract Infection

Analysis of efficacy and safety of panipenem/betamipron in treatment of 30 patients with severe bacterial infection

A Multicenter,randomized Controlled Clinical Trial of Imported Amoxicillin-Sulbactam in the Treatment of Community-Acquired Pneumonia

Pharmacokinetic study on piperacillin and sulbactam (4:1) injection in healthy volunteers

Efficacy of Cefoperazone/sulbactam 2∶1 Vs Cefoperazone/sulb Actam 1∶1 in Treatment of Lower Respiratory Tract Infections

Situation of Acinetobacter Baumannii Infection in Department of Neonatology and Evaluation of Sulbactam Treatment

Clinical evaluation of piperacillin/tazobactam

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections

Sulbactam Enhances in vitro Activity of -Lactam Antibiotics Against <i>Acinetobacter baumannii</i>

The Study on Antibacterial Activity of Amoxicillin Sulbactam Compared with Other Four Antimicrobial Agents in Vitro

Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations

Efficacy and safety of generic cefoperazone/sulbactam versus branded cefoperazone/sulbactam in the treatment of bacterial infections: a systematic review and meta-analysis

Assessing the therapeutic efficacy of Cefoperazone Sodium and Sulbactam Sodium in managing surgical site infections: a retrospective analysis

Cefoperazone/sulbactam in Treatment of Biliary Tract Infections: A Prospective Multicenter Clinical Trial

Efficiency of Polymyxin B Treatment Against Nosocomial Infection: a Systematic Review and Meta-Analysis

[Pharmacokinetic and clinical studies of sultamicillin fine granules in children]

Clinical evaluation of azithromycin